Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/15665
|
| Title: | Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan |
| Authors: | Cheng, SM;Su, YY;Chiang, NJ;Wang, CJ;Chao, YJ;Huang, CJ;Tsai, HJ;Chen, SH;Chang, CY;Tsai, CR;Li, YJ;Yen, CJ;Chuang, SC;Chang, JSM;Shan, YS;Hwang, DY;Chen, LT |
| Contributors: | National Institute of Cancer Research |
| Abstract: | BackgroundCancer susceptibility germline mutations are associated with pancreatic ductal adenocarcinoma (PDAC). However, the hereditary status of PDAC and its impact on survival is largely unknown in the Asian population.MethodsExome sequencing was performed on 527 blood samples from PDAC individuals and analyzed for mutations in 80 oncogenic genes. Pathogenic and likely pathogenic (P/LP) germline variants were diagnosed according to the ACMG variant classification categories. The association between germline homologous recombination gene mutations (gHRmut, including BAP1, BRCA1, BRCA2, PALB2, ATM, BLM, BRIP1, CHEK2, NBN, MUTYH, FANCA and FANCC) and the treatment outcomes was explored in patients with stage III/IV diseases treated with first-line (1L) platinum-based versus platinum-free chemotherapy.ResultsOverall, 104 of 527 (19.7%) patients carried germline P/LP variants. The most common mutated genes were BRCA2 (3.60%), followed by ATR (2.66%) and ATM (1.9%). After a median follow-up duration of 38.3-months (95% confidence interval, 95% CI 35.0-43.7), the median overall survival (OS) was not significantly different among patients with gHRmut, non-HR germline mutations, or no mutation (P = 0.43). Among the 320 patients with stage III/IV disease who received 1L combination chemotherapy, 32 (10%) had gHRmut. Of them, patients receiving 1L platinum-based chemotherapy exhibited a significantly longer median OS compared to those with platinum-free chemotherapy, 26.1 months (95% CI 12.7-33.7) versus 9.6 months (95% CI 5.9-17.6), P = 0.001. However, the median OS of patients without gHRmut was 14.5 months (95% CI 13.2-16.9) and 12.6 months (95% CI 10.8-14.7) for patients receiving 1L platinum-based and platinum-free chemotherapy, respectively (P = 0.22). These results were consistent after adjusting for potential confounding factors including age, tumor stage, performance status, and baseline CA 19.9 in the multivariate Cox regression analysis.ConclusionsOur study showed that nearly 20% of Taiwanese PDAC patients carried germline P/LP variants. The longer survival observed in gHRmut patients treated with 1L platinum-based chemotherapy highlights the importance of germline testing for all patients with advanced PDAC at diagnosis. |
| Date: | 2024-02-13 |
| Relation: | Journal of Biomedical Science. 2024 Feb 13;31:Article number 21. |
| Link to: | http://dx.doi.org/10.1186/s12929-024-01008-7 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1021-7770&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001161243900001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85185138820 |
| Appears in Collections: | [Li-Tzong Chen] Periodical Articles
[Dau-Yang Huang] Periodical Articles
[Jeffrey Shu-Ming] Periodical Articles
[Shang-Hung Chen] Periodical Articles
[Hui-Jen Tsai] Periodical Articles
[Yung-Yeh Su] Periodical Articles
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI001161243900001.pdf | | 3242Kb | Adobe PDF | 63 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
